CD40 and colitis: Taken together, these data demonstrated that CRISPR/Cas9-induced ablation of CD40 expression could effectively protect animals from colitis induction, and more importantly, our in vivo CRISPR/Cas9-based platform could be used to characterize gene function in colitis pathogenesis.